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Summary
Background The Global Point Prevalence Survey (Global-PPS) established an international network of hospitals to 
measure antimicrobial prescribing and resistance worldwide. We aimed to assess antimicrobial prescribing and 
resistance in hospital inpatients.
Methods We used a standardised surveillance method to collect detailed data about antimicrobial prescribing and 
resistance from hospitals worldwide, which were grouped by UN region. The internet-based survey included all 
inpatients (adults, children, and neonates) receiving an antimicrobial who were on the ward at 0800 h on one specific 
day between January and September, 2015. Hospitals were classified as primary, secondary, tertiary (including infectious 
diseases hospitals), and paediatric hospitals. Five main ward types were defined: medical wards, surgical wards, 
intensive-care units, haematology oncology wards, and medical transplantation (bone marrow or solid transplants) 
wards. Data recorded included patient characteristics, antimicrobials received, diagnosis, therapeutic indication 
according to predefined lists, and markers of prescribing quality (eg, whether a stop or review date were recorded, and 
whether local prescribing guidelines existed and were adhered to). We report findings for adult inpatients.
Findings The Global-PPS for 2015 included adult data from 303 hospitals in 53 countries, including eight lower-
middle-income and 17 upper-middle-income countries. 86 776 inpatients were admitted to 3315 adult wards, of 
whom 29 891 (34·4%) received at least one antimicrobial. 41 213 antimicrobial prescriptions were issued, of which 
36 792 (89·3%) were antibacterial agents for systemic use. The top three antibiotics prescribed worldwide were 
penicillins with β-lactamase inhibitors, third-generation cephalosporins, and fluoroquinolones. Carbapenems were 
most frequently prescribed in Latin America and west and central Asia. Of patients who received at least one 
antimicrobial, 5926 (19·8%) received a targeted antibacterial treatment for systemic use, and 1769 (5·9%) received a 
treatment targeting at least one multidrug-resistant organism. The frequency of health-care-associated infections 
was highest in Latin America (1518 [11·9%]) and east and south Asia (5363 [10·1%]). Overall, the reason for treatment 
was recorded in 31 694 (76·9%) of antimicrobial prescriptions, and a stop or review date in 15 778 (38·3%). Local 
antibiotic guidelines were missing for 7050 (19·2%) of the 36 792 antibiotic prescriptions, and guideline compliance 
was 77·4%.
Interpretation The Global-PPS showed that worldwide surveillance can be accomplished with voluntary participation. 
It provided quantifiable measures to assess and compare the quantity and quality of antibiotic prescribing and 
resistance in hospital patients worldwide. These data will help to improve the quality of antibiotic prescribing through 
education and practice changes, particularly in low-income and middle-income countries that have no tools to 
monitor antibiotic prescribing in hospitals.
Funding bioMérieux.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 4.0 
license.
Introduction
The paucity of information and data about the quantity 
and quality of antimicrobial prescribing is a key barrier 
to the successful development and implementation of 
antimicrobial stewardship programmes internationally.1 
Surveillance systems to monitor antimicrobial use and 
resistance are needed to improve decision making and 
assess the effect of interventions.2,3 Furthermore, auditing 
of, and feedback on, prescribing practices complements 
and improves4 other core stewardship interventions (eg, 
empirical therapy according to guidelines).5,6
The Global Point Prevalence Survey (Global-PPS) of 
Antimicrobial Consumption and Resistance was 
developed after the fourth World Healthcare-Associated 
Infections and Antimicrobial Resistance Forum. Its aim 
was to assess the international prevalence of antimicrobial 
use and resistance, with an emphasis on countries with 
low resources, support, and expertise.7 The project built 
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on the findings of three point prevalence surveys done by 
the European Surveillance of Antimicrobial Consumption 
Network between 2006 and 2009.8,9 Several studies9–12 of 
the applicability and benefits of point prevalence surveys 
of antimicrobial use showed their value in a range of 
European hospitals. Additionally, the European Surveil-
lance of Antimicrobial Consumption Network’s methods 
were adapted for the European Centre for Disease 
Prevention and Control point prevalence survey of 
health-care-associated infections and antimicrobial use 
in acute care hospitals,13 and for the Antibiotic Resistance 
and Prescribing in European Children project, which 
focused on antimicrobials administered to paediatric and 
neonatal patients worldwide.14–17
In this Article, we report the first Global-PPS, which 
was done in 2015, with a focus on antibiotic prescribing 
practices for patients admitted to adult hospital wards 
(ie, adult inpatients), to establish the variation in quantity 
and quality of antibacterial prescribing and resistance 
across continents.
Methods
Study design and setting
We did a cross-sectional audit of antimicrobial pre-
scribing practices and resistance at hospitals around the 
world. All hospitals admitting inpatients worldwide were 
welcome to join the Global-PPS, which was promoted 
through existing European Surveillance of Antimicrobial 
Consumption and Antibiotic Resistance and Prescribing 
in European Children hospital networks and at the 
2014 European Congress of Clinical Microbiology and 
Infectious Diseases, with help from bioMérieux 
subsidiaries and members of the Hospital-Acquired 
Infection/Antimicro bial Resistance Forum.7
The Global-PPS was piloted in 33 hospitals worldwide 
from Oct 1, 2014, to Nov 30, 2014. Several key amendments 
were made to the study after this pilot, including software 
improvements (no protocol amendments were made), 
before the full Global-PPS was done between Jan 1, 2015, 
and Sept 30, 2015. Data from hospitals that successfully 
participated in the pilot study were included in the final 
data analysis.
Hospitals in participating countries were grouped by 
UN region (ie, Africa, Americas, Asia, Europe, and 
Oceania),18 which were broken into subregions depending 
on the number of hospitals participating. The Americas 
region was divided into Latin America and the Caribbean 
(hereafter called Latin America because of an absence of 
data for the Caribbean) and North America. Asia was 
divided into two groups: east and south Asia (which 
includes south, east, and southeast Asia), and west and 
central Asia. Europe was divided into four subregions: 
eastern Europe, northern Europe, southern Europe, 
and western Europe.18 Hospitals were classified as 
primary, secondary, tertiary (including infectious diseases 
hospitals), and paediatric hospitals, as previously defined 
by the European Centre for Disease Prevention and 
Control.19 Overall, five main ward types were defined for 
adult and paediatric wards: medical wards, surgical 
wards, intensive-care units, haematology oncology wards, 
and medical transplantation (bone marrow or solid 
transplants) wards. For adult wards, we also included 
pneumology medical wards, whereas for children, 
neonatal intensive-care units and neonatal medical wards 
were included.
All study data were completely anonymised, and no 
unique identifiers were recorded. Furthermore, the 
survey did not require direct contact with patients. Thus, 
Research in context
Evidence before this study
We did not do a systematic search of published work to establish 
the usefulness of the Global Point Prevalence Survey. Surveillance 
systems monitoring antimicrobial use and resistance are the 
cornerstones of successful implementation of sustainable 
antimicrobial stewardship programmes. They improve decision 
making and enable assessment of the effects of interventions. 
A point prevalence survey is a well established method that is 
applicable and beneficial in European hospitals and beyond.
Added value of this study
In the Global Point Prevalence Survey, we assessed the 
prevalence of antimicrobial use and resistance worldwide. 
The study protocol was easy to follow, and we provided a 
simple tool for data entry and immediate feedback, enabling 
direct benchmarking with other hospitals and wards by country 
and region. Hospitals in low-income and middle-income 
countries could for the first time measure and compare 
antimicrobial use patterns at a local and regional level. 
The Global Point Prevalence Survey allowed sharing of best 
practice, raised awareness of inappropriate antimicrobial 
prescribing, and provided tangible, quantifiable quality 
indicators to improve antibiotic prescribing at hospital level.
Implications of all the available evidence
The Global Point Prevalence Survey complements WHO’s Global 
Antimicrobial Surveillance System (which provides a 
standardised approach for collection, analysis, and sharing of 
data for antimicrobial resistance) by providing a validated 
method for measuring the quality of antimicrobial prescribing 
and the effect of interventions to improve prescribing. 
Governments can use this tool to support antimicrobial 
stewardship frameworks as part of their WHO National Action 
Plans, and the UN’s Interagency Coordination Group on 
Antimicrobial Resistance could use it for international mapping 
of antimicrobial prescribing and resistance in hospitals, and to 
build a sustainable hospital surveillance framework with a focus 
on low-income and middle-income countries.
For more on the European 
Congress of Clinical 
Microbiology and Infectious 
Diseases see http://2014.eccmid.
org/
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patient consent was not required. Each patient record 
was given a unique but non-identifiable survey number, 
which was automatically generated. The need for ethics 
approval for this study varied by country, and was taken 
care of by participating hospitals on an individual basis if 
required. A data privacy excerpt document was available 
for this purpose.
Data collection 
Hospital-based doctors, pharmacists, and nurses were 
responsible for completing the Global-PPS. They were 
asked to do a 1-day survey, during which all wards had 
to be audited once. All inpatients who were on the ward 
at 0800 h were included. Total ward inclusion at the 
hospital level was requested but not mandatory 
(appendix). Data collection was done with two forms, 
one for ward-level data (ie, recording of denominators, 
such as the total number of inpatients on the ward) 
and one for patient-level data (recording of numerators; 
appendix). For each patient receiving at least one anti-
microbial, we gathered data about patient character-
istics, the antimicrobials received, their diagnosis, and 
the therapeutic indication according to predefined 
lists (appendix). Two major categories—treatment and 
prophylaxis—were used, each of which consisted of 
two main types of indication. The former category 
comprised therapeutic antimicrobial prescribing for 
both community-acquired and health-care-associated 
infections (infections that become symptomatic 48 h 
after hospital admission). The latter category included 
antimicrobial prescribing for both surgical and medical 
prophylaxis. For patients receiving surgical prophylaxis, 
administration had to be checked in the previous 24 h 
to encode the duration of prophylaxis as either one 
dose, one day (ie, multiple doses given in one day), or 
more than one day. 
Additional indicators of antimicrobial-prescribing 
quality were documentation of the diagnosis in the 
patient’s notes at the start of treatment, the choice of 
antibiotic being compliant with local guidelines, and 
docu men tation of a stop or review date for the 
antimicrobial in the notes. Additionally, empirical or 
targeted treatment (ie, based on microbiology data from a 
relevant clinical specimen, such as blood or sputum, 
excluding screening tests) was recorded. When treatment 
choice was made on the basis of available microbiology 
data, we recorded whether it targeted one of nine 
multidrug-resistant organisms (appendix). Finally, we 
recorded whether biomarker data (eg, C-reactive protein, 
procalcitonin, any other bio marker) were used to support 
prescribing decisions.
Antimicrobials included antibiotics for systemic use, 
antimycotics and antifungals for systemic use, drugs to 
treat tuberculosis, oral antibiotics prescribed as intestinal 
anti-infectives (eg, oral vancomycin), nitroimidazole 
derivatives, neuraminidase inhibitors, and antimalarials. 
All antimicrobials were automatically classified online 
according to the standardised and internationally 
recognised WHO anatomical therapeutic chemical 
classification system (2014 version).20 No discussion or 
personal judgment on the appropriateness of antibiotic 
prescribing was allowed during the survey.
All data were inputted into the freely available 
Global-PPS program, an internet-based application for 
anonymised data entry, validation, and reporting. A 
helpdesk and several supplementary documents, such as 
a frequently asked questions list, were freely available 
to support the participants. The British Society for 
Antimicrobial Chemotherapy also developed an e-learning 
course. Data validation included several built-in checks 
with error and warning messages that had to be managed 
by the user to generate a real-time feedback report. As a 
check on the completeness of data, participants had to 
record whether the whole hospital was surveyed. The 
software was also designed to prevent missing and 
erroneous data entry, such as inconsistencies between the 
indication and the diagnosis (eg, an antibiotic given for 
prophylactic use but prescribed for sepsis), extremely high 
total daily doses, and double entry of the same drug 
(appendix). Additionally, all hospitals with an overall 
antibiotic prescription prevalence higher than 70% were 
individually contacted to confirm the prevalence. All data 
were completely anonymised within the database and 
safeguarded at the University of Antwerp (Antwerp, 
Belgium). However, all data remained the property of the 
hospital.
Data analysis
We focus on prescribing of antibiotics for systemic use, 
which we report as the number of treated patients, the 
number of therapies, and the number of prescriptions. 
Therapy was defined as one treatment (ie, receiving at 
least one antibiotic) per diagnosis. A prescription was 
defined as the use of one substance by one route of 
administration. Antimicrobial prescribing rates were 
expressed as a percentage of patients on antimicrobials, 
or as a percentage of all antibiotic or antimicrobial 
prescriptions (proportional use). Means and ranges 
were aggregated at UN regional level,18 by ward type 
and indication. We ranked the number of antibiotics 
accounting for 90% and 75% of drug use. Antibiotic 
resistance patterns were expressed as the proportion of 
patients receiving at least one antibiotic targeting at 
least one resistant micro-organism of all patients for 
whom an antimicrobial result (ie, targeted treatment) 
was available.
Role of the funding source
The study funder had no role in the study design or data 
collection, analysis, or interpretation. IC, M-FG, and MM 
are employees of the funder, and had roles in the writing 
of the report. The corresponding author had access to all 
study data and had final responsibility for the decision to 
submit for publication.
See Online for appendix
For the e-learning course see 
http://www.futurelearn.com/
courses/point-prevalence-
surveys
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Results
335 hospitals in 53 countries (including eight lower-
middle-income and 17 upper-middle-income countries) 
were included in the Global-PPS (appendix). 18 hospitals 
had successfully participated in the pilot study. For this 
analysis, we excluded data from 32 hospitals: 22 paediatric 
hospitals (4091 patients), three hospitals that did not 
provide data for adult wards, and seven with denominator 
issues with ward-level data. Thus, 303 hospitals were 
eligible for inclusion in the final analysis.
The adult 2015 Global-PPS dataset included 45 primary 
care hospitals (5805 patients [6·7%]), 129 secondary care 
hospitals (31 790 patients [36·6%]), 107 tertiary care 
hospitals (44 873 patients [51·7%]), and 22 infectious 
diseases or specialised hospitals (4308 patients [5·0%]; 
appendix). The number of beds in participating hospitals 
ranged from 16 to 2387 beds (median 266 [IQR 131–459]). 
We collected data for 86 776 patients admitted to 
3315  adult wards. Overall, 15 564 (52·1%) of the 
29 861 patients treated on adult wards were male (ranging 
from 44·8% in North America to 58·5% in 
eastern Europe).
41 213 antimicrobial prescriptions were issued. Anti-
bacterials for systemic use accounted for 36 792 (89·3%)
prescriptions, antimycotics and antifungals for systemic 
use for 1724 (4·2%) prescriptions, drugs to treat 
tuberculosis for 1053 (2·6%) prescriptions, nitro-
imidazole derivatives for 835 (2·0%) prescriptions, 
antibiotics prescribed as intestinal anti-infectives for 
692 (1·7%) prescriptions, and neuraminidase inhibitors 
for 117 (0·3%) prescriptions. Antimicrobial use varied 
between continents (from 27·4% in eastern Europe to 
50·0% in Africa) and by ward type (from 29·0% in 
medical wards to 77·0% in transplant wards; table 1). 
36 792 antibacterials for systemic use were used in 
patients admitted to adult wards on the day of the survey, 
including 139 different agents (appendix). 31 antibacterials 
accounted for 90% of drug use in east and south Asia, 
compared with 15 in Africa and 13 in eastern Europe. 
The combination of penicillins with a β-lactamase 
inhibitor was the most commonly prescribed class, 
mainly amoxicillin with β-lactamase inhibitors (11·4%) 
and piperacillin with β-lactamase inhibitors (7·7%) 
(appendix). The second and third most commonly 
prescribed antibiotics were third-generation cephalo-
sporins (mainly ceftriaxone) and fluoroquinolones 
(mainly ciprofloxacin and levofloxacin; appendix).
The top five indications for antibiotic prescription—
pneumonia or lower respiratory tract infections, skin and 
soft tissue infections, intra-abdominal infections, 
lower urinary tract infections, and upper urinary tract 
infections—accounted for 13 703 (45·9%) treated patients 
(table 2). Pneumonia was overall the most common 
indication, accounting for 5722 (19·2%) of treated 
patients worldwide (table 2). Overall, 16 781 (45·6%) 
antibiotics were prescribed for community-acquired 
infections (table 3). Targeted prescribing was more 
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common for health-care-associated infections (36·9%) 
than for community-acquired infection (20·9%; table 3).
Overall 7278 (8·4%) of 86 776 adult inpatients were 
treated with antibacterials for systemic use for at least 
one health-care-associated infection. 66 (2·8%) of patients 
in eastern Europe, 1064 (7·5%) in southern Europe, 
2322 (7·7%) in western Europe, 321 (8·7%) in western 
and central Asia, 714 (8·8%) in northern Europe, 
225 (8·9%) in Oceania, 533 (9·6%) in North America, 
1457 (10·1%) in east and south Asia, and 489 (11·9%) in 
Eastern 
Europe 
(n=646)
Northern 
Europe 
(n=2791)
Southern 
Europe 
(n=5452)
Western 
Europe 
(n=8414)
Africa 
(n=870)
East and 
south Asia* 
(n=5402)
West and 
central Asia 
(n=1626)
Oceania 
(n=967)
Latin 
America 
(n=1554)
North 
America 
(n=2139)
Total 
(n=29 861)
Pneumonia or lower respiratory tract infection 15·2% 28·2% 14·3% 23·3% 10·3% 16·2% 14·8% 19·0% 16·5% 21·1% 19·2%
Skin and soft tissue infections† 13·5% 9·1% 6·7% 8·0% 16·2% 8·2% 7·9% 15·6% 12·5% 11·6% 9·0%
Intra-abdominal infections‡ 1·2% 8·3% 5·6% 7·1% 3·8% 7·8% 5·2% 9·1% 10·2% 7·4% 7·0%
Lower urinary tract infections (cystitis) 0·5% 6·7% 4·3% 8·1% 2·4% 3·5% 4·6% 8·5% 5·5% 11·2% 6·0%
Upper urinary tract infections§ 4·6% 5·9% 4·3% 4·9% 1·4% 4·5% 5·3% 3·6% 6·0% 4·3% 4·7%
Prophylaxis for bone and joint infections¶ 7·6% 2·4% 6·3% 4·7% 6·6% 4·4% 3·1% 6·1% 4·1% 3·5% 4·7%
Upper respiratory tract infection (acute bronchitis or 
chronic exacerbations)
5·6% 3·5% 4·5% 7·3% 0·7% 1·1% 5·2% 3·0% 1·8% 2·9% 4·2%
Prophylaxis for gastrointestinal infections|| 6·3% 1·8% 8·1% 2·4% 2·8% 4·3% 8·2% 1·7% 5·3% 1·7% 4·2%
General prophylaxis 2·8% 2·3% 5·0% 2·7% 2·9% 5·9% 1·2% 5·0% 3·9% 3·5% 3·8%
Unknown 0·8% 3·5% 2·7% 2·9% 11·4% 3·0% 2·0% 1·9% 1·7% 4·0% 3·1%
Prophylaxis for obstetric or gynaecological infections 
(surgery)
3·9% 2·5% 4·4% 0·9% 9·8% 4·4% 3·8% 1·3% 2·9% 2·6% 3·0%
Bone or joint infections** 3·4% 2·2% 1·6% 3·5% 3·0% 2·4% 3·3% 3·7% 2·6% 3·4% 2·8%
Sepsis†† 0·2% 3·9% 2·1% 2·3% 3·8% 2·8% 4·5% 0·7% 2·6% 3·8% 2·7%
Prophylaxis for urinary tract infections (surgery or 
recurrent infections)
5·3% 2·0% 3·4% 2·8% 1·7% 1·5% 4·5% 2·6% 2·8% 1·3% 2·6%
Gastrointestinal infections 4·8% 1·5% 2·3% 2·3% 2·4% 2·3% 4·4% 1·4% 1·7% 2·9% 2·4%
Patients recorded with more than one diagnosis were counted by number of diagnoses. Patients not treated with antibiotics for systemic use, but who were treated with other antimicrobials (eg, antimalarials) 
were not included. A version of this table containing numerical data for all percentages is in the appendix. *Includes south, east, and southeast Asia. †Includes cellulitis, wound infections (including surgical site 
infections), deep soft tissue infections not involving bone (eg, infected pressure or diabetic ulcers, abscesses). ‡Includes intra- abdominal sepsis and hepatobiliary and intra-abdominal abscesses. §Includes 
catheter-related urinary tract infections and pyelonephritis. ¶Includes prophylaxis for skin and soft-tissue infections, and for plastic or orthopaedic surgery. ||Includes prophylaxis for surgery of the 
gastrointestinal tract, liver, or biliary tree, and prophylaxis in patients with neutropenia or hepatic failure. **Includes septic arthritis (including prosthetic joints) and osteomyelitis. ††Includes sepsis syndrome or 
septic shock with no clear anatomical site.
Table 2: Most common reasons to treat adult inpatients with at least one antibiotic for systemic use, 2015
Total 
antibiotic 
prescriptions
Therapeutic use Prophylactic use
Community-acquired 
infection
Community-acquired 
infection 
(targeted prescribing)
Health-care-associated 
infection
Health-care-
associated infection 
(targeted prescribing)
Medical Surgical
Eastern Europe 708 46·5% 12·2% 11·6% 34·1% 23·7% 17·5%
Northern Europe 3536 56·3% 14·1% 25·1% 20·4% 5·8% 9·5%
Southern Europe 6837 36·7% 16·6% 20·6% 41·3% 8·2% 29·2%
Western Europe 9485 51·0% 27·1% 28·3% 43·4% 5·9% 12·0%
Africa 1213 57·4% 19·5% 9·5% 33·9% 3·5% 23·2%
East and south Asia* 6781 36·9% 22·2% 27·7% 31·7% 9·8% 21·3%
West and central Asia 2084 44·8% 13·4% 20·9% 36·8% 7·7% 23·2%
Oceania 1226 53·3% 23·1% 23·6% 38·4% 7·6% 12·6%
Latin America 2170 41·4% 19·1% 34·9% 44·1% 5·6% 16·0%
North America 2752 52·2% 22·8% 26·1% 31·2% 5·1% 8·6%
Total 36 792 45·6% 20·9% 25·2% 36·9% 7·4% 17·8%
Data are n or %. Overall, 486 antibiotic prescriptions were recorded for another indication, and 1009 had an unknown indication; these antibiotics are not listed in the table. 
A version of this table containing numerical data for all percentages is in the appendix. *Includes south, east, and southeast Asia.
Table 3: Antibiotic use by indication and type of treatment (ie, targeted vs empirical) for adult inpatients in 2015, by region
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Latin America were treated with such antibacterials. The 
most frequently reported indications (appendix) were 
non-intervention-related or other health-care-associated 
infections (3667 [4·2%] patients), followed by post-
operative surgical site infections (1382 [1·6%] patients).
The most prescribed antibiotics for health-care 
associated infections were penicillins with a β-lactamase 
inhibitor (24·8%), of which piperacillin with a β-lactamase 
inhibitor accounted for 14·6% and amoxicillin and 
a β-lactamase inhibitor for 8·9% (figure 1). Fluoro-
quinolones were the second most prescribed (12·8%), 
followed by carbapenems (mainly meropenem; 12·2%) 
and glycopeptides (mainly vancomycin; figure 1). The 
most commonly prescribed antibiotics for community-
acquired infections were penicillins with a β-lactamase 
inhibitor (29·2%), of which amoxicillin with a β-lactamase 
inhibitor accounted for 16·3% and piperacillin with a 
β-lactamase inhibitor accounted for 7·7% (figure 2). 
Third-generation cephalosporins were the second most 
commonly prescribed (mainly ceftriaxone; 15·5%) anti-
biotics for community-acquired infections, followed by 
fluoro quinolones (14·0%; figure 2).
7546 (26·3%) adult patients receiving antibiotics, ranging 
from 419 (15·6%) in northern Europe to 282 (43·9%) in 
eastern Europe, were given at least one antibiotic for 
prophylaxis. The overall mean prevalence for surgical 
prophylaxis was 17·8% (table 3). Cefazolin was the 
most commonly prescribed antibiotic for surgical 
prophylaxis (accounting for 1801 [27·5%] of the 6538 pre-
scriptions), with the highest prescribing rates noted in 
Oceania (prescribed to 100 [64·5%] of the 155 patients who 
were prescribed surgical prophylaxis), North America 
(148 [62·4%] of 237 patients), and western Europe 
(655 [57·7%] of 1136 patients). Ceftriaxone was the most 
commonly prescribed antibiotic for surgical prophylaxis 
in eastern Europe (49 [39·5%] of 124 patients), southern 
Europe (559 [28·0%] of 1995  patients), and Africa (78 
[27·7%] of 282 patients). Prolonged surgical prophylaxis 
(ie, >1 day) was very common in all regions (range 40·6% in 
Oceania to 86·3% in eastern Europe; appendix). Overall, 
mean pre valence of medical prophylaxis was 7·4% (2717 of 
the 36 729 anti biotics prescribed; table 3). Many different 
antibiotics were used for medical prophylaxis, but 
sulfamethoxazole–trimethoprim was the most commonly 
prescribed worldwide, and accounted for 63·4% (59 of 
93 patients) of all medical prophylactic prescribing in 
Oceania and 56·0% (371 of 663 patients) in east and 
south Asia. Ceftriaxone was the most commonly pre-
scribed in eastern Europe (91 [54·2%] of 168 patients), 
southern Europe (95 [16·9%] of 561 patients), and west and 
central Asia (27 [16·9%] of 160 patients).
The stop or review date for antibiotic treatment was 
poorly documented overall (38·3% of antimicrobial 
prescriptions; table 4). Of 29 891 treated patients, 
5926 (19·8%) received at least one targeted antibacterial 
treatment for systemic use, and 1769 (5·9%) received a 
treatment targeting at least one multidrug-resistant 
Figure 1: Proportion of prescribed antibiotics for systemic use for health-care-associated infections among 
adult inpatients, 2015 (n=9261)
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Figure 2: Proportion of prescribed antibiotics for systemic use for community-acquired infections among 
adult inpatients, 2015 (n=13 226)
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organism (table 4). Overall, 58·3% of these patients 
received antibiotics targeting Gram-negative bacteria, 
with the highest proportional numbers noted in 
eastern Europe (appendix). Only in North America did a 
higher proportion of patients receive targeted treatment 
against Gram-positive bacteria than against Gram-
negative bacteria. Table 5 shows the prevalence of 
patients receiving targeted treatment against resistant 
bacteria.
Discussion
We showed the feasibility of doing the Global-PPS, which 
focused on antibiotic prescribing and resistance, with a 
simple and affordable method on an international scale. 
Many hospitals assessed antibiotic prescribing patterns 
and collected information about antibiotic resistance in 
their hospital for the first time. These data are essential for 
development of antimicrobial stewardship programmes. 
Other point prevalence surveys have been done 
successfully in high-income countries in the European 
Union and the USA,21,22 but our simple Global-PPS tool 
also allowed for the participation of many hospitals in low-
income and middle-income countries.
We identified substantial differences in the prevalence 
of antibiotic prescribing between and within regions or 
countries, with the highest prevalence in Africa (50·0%; 
country range 27·8–74·7) and the lowest in eastern Europe 
(27·4%; 23·7–27·8). The overall prevalence for Europe 
(31·9%; 23·7–62·0) was similar to the weighted prevalence 
of previous point prevalence surveys in Europe in 2011–12 
(32·6%; range 21·4 [France]–54·7 [Greece]),21 but lower 
than that in a survey done in 183 US hospitals in 2011 
(49·9% [95% CI 49·0–50·9).22 Combinations of penicillins 
with a β-lactamase inhibitor were the most frequently 
prescribed antibiotic class in this survey, largely because 
of high prescribing rates in northern and western Europe 
(and particularly in Belgian hospitals; appendix). Third-
generation cephalosporins, mainly ceftriaxone, were the 
next most commonly prescribed, with a high frequency of 
prescription in Asia, Latin America, and southern and 
eastern Europe for both community-acquired and health-
care-associated infections. The frequent use of ceftriaxone 
in these regions suggests that at least a proportion of this 
prescribing could be inappropriate.
Fluoroquinolones were the third most commonly 
prescribed antibiotics, because of frequent use of levo-
floxacin in hospitals in North America and east and 
south Asia (mainly for pneumonia in both cases) and of 
ciprofloxacin in western Europe (mainly for cystitis) and 
elsewhere in Europe (for various indications). Striking 
differences in levofloxacin use were noted in the Americas 
(12·8% in North America vs 1·2% in Latin America) and 
Asia (7·4% in east and south Asia vs 0·9% in west and 
central Asia; appendix). Differences in cost of, or access 
to, fluoroquinolones could preclude their use in some 
countries. These differences in prescribing patterns 
could also be due to marketing strategies or differing 
antibiotic regulations. A remarkably high frequency of 
vancomycin use was noted in North American and 
Latin American hospitals (appendix). This high 
vancomycin use can be explained by the high prevalence 
of meticillin-resistant Staphylococcus aureus (MRSA) 
infection reported in Latin American hospitals,23 which is 
in line with the high proportion of patients who received 
Antimicrobial 
prescriptions
Antibiotic 
prescriptions
Targeted 
treatment*
Targeted 
treatment 
(resistant 
organisms)*
Reason 
recorded†
Stop or review 
date recorded†
Parenteral 
administration‡
Guidelines 
available§
Compliant 
to local 
guidelines¶
No guidelines 
available||
Eastern Europe (n=653) 747 708 51 (7·8%) 42 (6·4%) 64·3% 50·5% 87·6% 79·8% 85·7% 19·2%
Northern Europe (n=2783) 3880 3536 396 (14·2%) 80 (2·9%) 81·4% 51·6% 62·2% 90·0% 83·4% 6·5%
Southern Europe (n=5534) 7674 6837 838 (15·1%) 292 (5·3%) 69·5% 29·1% 80·0% 60·5% 70·8% 29·6%
Western Europe (n=8458) 10612 9485 2204 (26·1%) 469 (5·5%) 80·5% 40·3% 64·0% 81·0% 78·7% 10·1%
Africa (n=899) 1502 1213 131 (14·6%) 25 (2·8%) 70·4% 36·6% 62·7% 49·5% 67·9% 26·7%
East and south Asia** 
(n=5363)
7607 6781 938 (17·5%) 287 (5·4%) 74·6% 43·5% 71·8% 76·4% 81·5% 21·4%
West and central Asia 
(n=1612)
2252 2084 236 (14·6%) 153 (9·5%) 72·8% 19·8% 85·2% 53·4% 66·3% 40·5%
Oceania (n=932) 1411 1226 218 (23·4%) 63 (6·8%) 85·1% 27·0% 60·5% 87·4% 73·2% 11·7%
Latin America (n=1518) 2403 2170 403 (26·5%) 231 (15·2%) 81·4% 40·3% 84·4% 76·5% 64·1% 19·9%
North America (n=2139) 3125 2752 511 (23·9%) 127 (5·9%) 84·9% 39·6% 73·1% 77·3% 85·8% 18·5%
Total (n=29 891) 41 213 36 792 5926 (19·8%) 1769 (5·9%) 76·9% 38·3% 71·4% 74·3% 77·4% 19·2%
Data are n or %. A version of this table containing numerical data for all percentages is in the appendix. *Patients receiving at least one antibiotic for systemic therapeutic use only (ie, health-care-associated or 
community-acquired infection). †Includes all antimicrobials; the total number of antimicrobial prescriptions was used to calculate percentages. ‡Patients who received at least one parenteral antibiotic for 
systemic use. §Antibiotic prescriptions for which guidelines were available to guide antibiotic choice (not route, dose, or duration), which was calculated as all antibiotic prescription for which a local guideline 
was available/all antibiotic prescription. ¶The number of antibiotic prescriptions for which guidelines were available was used as the denominator to calculate percentages. ||The total number of antibiotic 
prescriptions was used as the denominator to calculate percentages. **Includes south, east, and southeast Asia.
Table 4: Overview of antimicrobial and antibiotic quality indicators for adult inpatients by region, year 2015
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targeted treatment against MRSA infections in our 
survey (table 5). Carbapenems (mainly meropenem) 
were widely prescribed in Latin America and Asia, 
probably because of the high frequency of infections 
caused by extended-spectrum β-lactamase-producing 
Gram-negative bacteria (table 4), which has been reported 
in previous surveillance studies.24–26
The most frequent indication for antibiotic therapy 
worldwide was pneumonia, followed by urinary tract 
infections. More in-depth analyses are needed to establish 
the proportion of health-care-associated urinary tract 
infections caused by extended-spectrum β-lactamase-
producing organisms. We noted a high proportion of 
prophylaxis for a range of indications, but unusually high 
prophylactic prescribing for gastrointestinal infections in 
west and central Asia. Further research is warranted to 
explain the reasons for this pattern.
To identify inappropriate antibiotic prescribing, we 
investigated five indicators of quality, which could easily 
be used to set benchmarks for quality improvement of 
antibiotic use in hospitals.11 Documentation of the reason 
for prescription ensures communication of diagnosis 
and treatment among clinicians and other health-care 
providers, and allows for recording of prescription stop or 
review dates and other interventions such as de-escalation. 
In northern and western Europe, the Americas, and 
Oceania, findings for this indicator were similar to those 
in the 2009 European Surveillance of Antimicrobial 
Consumption point prevalence survey among European 
adults (80%).9 Frequency of documentation of the reason 
for the pre scription was less common in hospitals in 
eastern (64%) and southern (70%) Europe, Africa (70%), 
and Asia (73%; table 3).
The second indicator, formal review of the appro-
priateness of an antimicrobial administered within 48 h 
of the initial order (post-prescription review),27 refers 
to  the existence of a policy or agreed intervention 
preventing unnecessarily long antibiotic courses and 
ensures that the chosen antibiotic and its route of 
administration is still appropriate. Such a policy can 
reduce selection pressure, and prevent adverse effects 
such as drug-related toxicity and damage to the normal 
intestinal bacterial flora leading to Clostridium difficile 
infection. A stop or review date was recorded for less 
than a third of antimicrobials pre scribed in south-
ern Europe, west and central Asia, and Oceania (table 3). 
This review process should be targeted as a key 
intervention, and the effects of such intervention should 
be measured with repeated point prevalence surveys.11
Parenteral administration, the third quality indicator, 
was most common in west and central Asia, Latin 
America, and eastern and southern Europe, where it 
accounted for more than 80% of patients on anti biotics. 
Broad-spectrum antibiotics are commonly administered 
in these regions (such as third-generation cephalo-
sporins), and broad-spectrum oral antibiotics are scarce. 
The switch from intravenous to oral anti biotics has many 
advantages, including reductions in catheter-related 
complications, health-care costs, and duration of hospital 
stays, and is recognised as a key metric for stewardship 
processes in hospitals.27,28 However, to what extent 
different administration routes affect antimicrobial 
resistance is not known.29
The fourth quality indicator referred to the existence of, 
and adherence to, antibiotic treatment guidelines. In 
west and central Asia, local guidelines were not available 
MRSA MRCoNS VRE ESBL Third-generation 
cephalosporin-resistant 
Enterobacteriaceae*
Carbapenem-resistant 
Enterobacteriaceae
ESBL-producing 
non-fermenting 
Gram-negative 
bacilli
Carbapenem-resistant 
non-fermenting 
Gram-negative bacilli
Other 
multidrug-resistant 
organisms
Eastern Europe (n=53) 7·5% 1·9% ·· 37·7% 5·7% ·· 15·1% 20·8% 3·8%
Northern Europe (n=435) 5·3% 0·7% 1·6% 6·0% 0·9% 0·2% 0·2% 1·8% 2·3%
Southern Europe (n=1021) 5·0% 2·2%% 2·9% 8·4% 1·5% 2·1% 2·8% 3·6% 4·9%
Western Europe (n=2472) 3·4% 1·8% 0·2% 7·1% 3·0% 0·4% 0·5% 0·6% 2·8%
Africa (n=170) 1·2% 0·6% ·· 5·3% 0·6% ·· 1·8% 2·4% 2·9%
East and south Asia 
(n=1070)†
6·2% 2·8% 0·9% 6·5% 3·6% 2·1% 1·7% 3·6% 2·4%
West and central Asia 
(n=266)
9·8% 1·1% 0·8% 13·9% 3·8% 3·0% 6·8% 7·5% 15·0%
Oceania (n=227) 4·8% 1·8% 1·8% 6·6% 2·6% 0·4% 11·5% 1·8% 0·9%
Latin America (n=450) 10·4% 4·9% 1·3% 19·1% 4·4% 4·0% 2·4% 1·1% 4·4%
North America (n=586) 7·8% 2·0% 1·4% 4·3% 2·9% ·· 1·4% 5·1% 3·1%
Total (n=6750) 5·3% 2·1% 1·1% 8·1% 2·8% 1·2% 2·0% 2·6% 3·6%
Targeted treatment is treatment based on microbiological results—ie, any culture or sensitivity result from a relevant clinical specimen (eg, blood, sputum), excluding screening specimens, or any other 
microbiology result (eg, Legionella urinary antigen). Patients could be counted more than once depending on the number of targeted antibiotics administered for more than one resistant microorganism. A version 
of this table containing numerical data for all percentages is in the appendix. MRSA=meticillin-resistant Staphylococcus aureus. MRCoNS=meticillin-resistant coagulase-negative staphylococci. 
VRE=vancomycin-resistant enterococci. ESBL=Extended-spectrum β-lactamases. *Non-ESBL producing, or ESBL status unknown. †Includes south, east, and southeast Asia.
Table 5: Prevalence of resistant organisms in adult inpatients who received targeted antibiotics in 2015, by region
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for 40·5% of antibiotic prescriptions, especially for 
medical prophylaxis in the absence of a clear diagnosis 
(tables 2, 3). In one African country, 11% of patients were 
treated with antibiotics for an unknown diagnosis, 
contrary to guidelines for low-income and middle-
income countries that state “an appropriate treatment 
must be preceded by diagnoses that ensures the correct 
clinical path”.30 Correct diagnosis and treatment 
planning necessitate the existence of a clinical 
microbiology laboratory and antimicrobial stewardship 
involvement—eg, daily laboratory rounds.31 Guideline 
compliance referred only to the choice of drug for 
therapeutic or prophylactic use. Overall mean com-
pliance to guidelines was 77·4%, but compliance was less 
than 70% in Latin America, west and central Asia, and 
Africa. Next to developing and updating local treatment 
guidelines, adherence to guidelines could improve 
clinical outcomes—eg, mortality, treatment duration, 
and length of hospital stay.32 A systematic review and 
meta-analysis6 showed that guideline-adherent empirical 
therapy was associated with a significant relative risk 
reduction for mortality of 35%. The reason for poor 
compliance with guidelines is uncertain and probably 
multifactorial. Local resistance patterns, clinical 
uncertainty, and fear of treatment failure could all have 
roles. Our data will enable further detailed investigation 
at a country and hospital level.
The fifth quality indicator concerned prolonged surgical 
prophylaxis, which was common in our survey (par-
ticularly in southern [85%] and eastern [86·3%] Europe) 
and in previous studies done in Europe.21 Antibiotic 
prophylaxis for more than 24 h for most surgical 
indications does not prevent development of postoperative 
infections compared with surgical prophylaxis for 24 h or 
less, but increases the risk of antimicrobial resistance and 
side-effects.33 In the absence of preoperative infection or 
severe complications, prolonged post operative antibiotic 
prophylaxis is unnecessary.34
The strengths of our study include the uniformity of 
data collection, the simplicity of the protocol and data 
collection templates, data completeness and validation 
via the internet-based tool, and the opportunity for real-
time educational feedback of results to participating 
centres (including comparisons with national and 
regional results).10 Although we had to rely on 
participants’ professionalism and motivation to provide 
valid data, we implemented strict online checks to avoid 
erroneous or incomplete data. Minimal training was 
required, and most hospitals successfully participated in 
the survey with help from the online supporting 
materials (eg, frequently asked questions), helpdesk 
support, and the e-learning course. The simple protocol 
and tool for data entry and feedback allowed for inclusion 
of hospitals from lower-middle-income (n=8) and upper-
middle-income countries (n=17; appendix).
The study, which was done on a voluntary basis with few 
resources (in terms of finance, IT, and workforce), 
provided a good utility value for the required time 
commitment. It also encouraged clinical prescriber buy-
in, particularly because the data accrued were fed back to 
the prescribers,35 the development of a sustainable 
network, and the construction of a huge database allowing 
the production of various analyses and publications at 
international, regional, and local levels. This Global-PPS 
not only contributes to continued worldwide awareness 
about antibiotic use and resistance, but also helps 
participants to set targets to improve antibiotic prescribing, 
thereby driving improved prescribing behaviour.11
The limitations of this study are inherent to the 
epidemiological methods of our cross-sectional survey, in 
which the main purpose was to describe prescribing 
patterns in hospitals.14 The overall rates provided are 
averages. We did not control for patient case mix, disease 
incidence, prevalence of different types of infections, 
variations in resistance levels, institutional factors, or 
differences in climates and seasons, among other factors, 
all of which can influence antibiotic use patterns. Thus, 
we urge caution in interpretation of the reported 
prevalences. Although we noted substantial differences 
in the prevalence of antibiotic prescribing between and 
within regions or countries, our data are not representative 
for most of these countries and regions. For instance, 
northern Europe was mainly presented by the UK, and 
data for western Europe included most Belgian hospitals 
because of coordination by the Belgian Antibiotic Policy 
Coordination Committee at federal level.36 Western 
European results might therefore be biased by typical 
Belgian prescribing practices (eg, the high use of 
amoxicillin with a β-lactamase inhibitor). We hope that in 
future surveys, countries could participate with a 
representative number of hospitals, which would allow 
more meaningful analysis at country and regional level.
The Global-PPS was repeated in 2017, with increased 
participation. We focused again on low-income and 
middle-income countries because our survey tool is the 
only means available for measurement of antibiotic 
prescribing in hospitals in these countries, which often 
have the highest prevalence of antibiotic prescribing and 
resistance. We aim to do repeated point prevalence 
surveys at hospital or ward level (yearly or quarterly) 
to measure the effect of antimicrobial stewardship 
interventions. Governments can use the Global-PPS tool 
to support the antimicrobial stewardship framework as 
part of their WHO National Action Plan. In some 
countries (eg, Belgium, the Philippines, Saudi Arabia), 
the Global-PPS was endorsed by their ministries of 
health, which invited hospitals to participate in the 
2017 edition. The UN Interagency Coordination Group on 
Antimicrobial Resistance could use the Global-PPS tool 
to map international antimicrobial prescribing and 
resistance in hospitals and to build a sustainable hospital 
surveillance framework, with a focus on low-income 
and middle-income countries. The Global-PPS could 
complement WHO’s Global Antimicrobial Resistance 
For an assessment of the time 
commitment in the Global-PPS 
see http://www.global-pps.com/
documents
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Surveillance System (GLASS).3 Ultimately, we aim to 
develop appropriate benchmarking standards, including 
quantifiable quality targets, but recognise the substantial 
pitfalls associated with use of these quantitative data for 
benchmarking.37 We are also developing an educational 
framework and training programme for health-care 
professionals working on hospital antimicrobial steward-
ship in low-income and middle-income countries.
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